european technology platform nanomedicine 106/12/2006 paul smit, philips paul smit november 2006
TRANSCRIPT
EUROPEAN TECHNOLOGY PLATFORMNANOMEDICINE
Paul Smit, Philips 1 06/12/2006
Paul Smit
November 2006
EUROPEAN TECHNOLOGY PLATFORMNANOMEDICINE
Paul Smit, Philips 2 06/12/2006
Healthcare Expenditures will grow from ~9% of worldwide GDP to ~11% in 2015
The Americas makes up 56%of the worldwide spend
Source: Medistat
0%
2%
4%
6%
8%
10%
1950 2005 2015
Source: WHO, Philips Internal Analysis
Healthcare is the world’s largest service sector
30%
2%
8%
1% 5%
54%
Americas
Europe, Mid-East,Africa
China/HK
J apan
India
Rest of Asia
Worldwide Healthcare Expenditure: US$3,834 bln in 2004
EUROPEAN TECHNOLOGY PLATFORMNANOMEDICINE
Paul Smit, Philips 3 06/12/2006
Key Challenges in Medicine
• Translating breakthroughs in understanding of disease into preventive medicine
• How to increase productivity dramatically
• How to align reimbursement with better outcome and efficiency
• How to design affordable healthcare for the bottom-of-the-pyramid
• How to reap the benefits of healthcare while reducing the ineffeciencies
• largest factor of a country’s economic growth
EUROPEAN TECHNOLOGY PLATFORMNANOMEDICINE
Paul Smit, Philips 4 06/12/2006
NanoMedicine is about early diagnosis and “preventive” treatment
Through screening and early diagnosis find disease early and intervene early
Symptoms
time
Clinical Symptoms
TreatmentFollow-upDiagnosisScreening
Current, Symptomatic Medicine
Preventive Medicine
Early Diagnosis
Preventive Treatment
EUROPEAN TECHNOLOGY PLATFORMNANOMEDICINE
Paul Smit, Philips 5 06/12/2006
The NanoMedicine Research Agenda1. Nanodiagnostics: early and accurate tests
- biosensors, miniaturized devices which handle nano samples- targeted imaging agents to highlight pockets of disease
2. Targeted Drug Delivery: on the spot- bring the drug to the target site and monitor its impact
3. Regenerative Medicine: stimulated repair- help the body to (re)build organs or systems
For the main diseases in the world:Cancer, cardiovascular disease, musculo-skeletal, mental and
infectious disease, and diabetesKeratinocyte on a microperforated membrane, pore size 60 micronsFidia Advanced BiopolymersAlessandra Pavesio
Courtesy of Sam Wickline, Greg Lanza, WashU St Louis
EUROPEAN TECHNOLOGY PLATFORMNANOMEDICINE
Paul Smit, Philips 6 06/12/2006
Key Policy Issues
1. Regulatory: Imaging agents are approved as if they are drugs for treatment – too long and too costly
2. Adoption rate in Healthcare of new technologies is very slow – proper incentives needed
3. Limited Venture Capital expertise and availability
4. Intellectual Property legislation fragmented across Europe, and
• Different models in converging industries
5. Risk of negative public perception of “Nano”
EUROPEAN TECHNOLOGY PLATFORMNANOMEDICINE
Paul Smit, Philips 7 06/12/2006
Acknowledgement
Thanks to the Team: ~150 members of the ETP NanoMedicine, and especially:
Patrick Boisseau Uta FaureMike Eaton Oliver PanzerAlessandra PavesioKlaus Michael WeltringMaaike van VelzenSebastian SchmittKarl-Jurgen Schmidt